June 2, 2025: When Arcturus announced, “that the FDA has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1,”on April 10,2025, many MAHA influencers responded in sharp criticism of the FDA fast-tracking saRNA technology.
Why? Because saRNA technology (which is part of the mRNA lipid nanoparticle portfolio) is the flagship US government funded dual-use platform used to create bioweapons ranging from SARS-CoV-2 and H15N1 biosynthetic viruses to COVID-19 mRNA ‘vaccines.’
SARS-CoV-2 Is a sa-mRNA Lipid Nanoparticle Pathogen
Click this link for the original source of this article.
Author: Karen Kingston
This content is courtesy of, and owned and copyrighted by, https://karenkingston.substack.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
